PITTSBURGH, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines, today reported financial results and key operational updates for the fourth quarter and year ending December 31, 2022.
“In 2022, we were focused on advancing B-VEC toward approval and getting commercially prepared for a potential launch this year, and I thank the entire Krystal team for their dedication and perseverance in helping us achieve our objectives,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc. He added, “Our focus in 2023 will be on advancing our pipeline and demonstrating the breadth of our gene delivery platform. We plan to have ASTRA, our second manufacturing facility, operational early this year which will enable us to advance our pipeline products in a timely manner.”
Dermatology
B-VEC (beremagene geperpavec) for Dystrophic Epidermolysis Bullosa (DEB)
Rare Dermatological Pipeline
Respiratory
KB407 for the treatment of Cystic Fibrosis (CF)
KB408 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Aesthetics
KB301 for the treatment of Aesthetic Indications
Fourth Quarter and Full Year 2022 Financial Results:
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
About Jeune Aesthetics, Inc.
Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to develop products to fundamentally address – and reverse – the biology of aging and/or damaged skin. For more information, please visit http://www.jeuneinc.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including statements about the B-VEC PDUFA date of May 19, 2023; our focus in 2023 on advancing our pipeline and demonstrating the breadth of our gene delivery platform; our plans to have our second manufacturing facility operational; the timing of the Company’s EMA marketing authorization application for B-VEC; our expectations regarding initiating dosing in the Phase 2 cohort of our KB105-02 (JADE-1) trial; our plans to file an investigational new drug application for KB104; our plan to initiate a Phase 1 dose ranging clinical (CORAL-1) trial for KB407 in the US in the first half of 2023; our plans to initiate a Phase 1 clinical trial for KB408 for the treatment of AATD; our plans for the commencement of a Phase 2 study of KB301; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption “Risk Factors” in the Company’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
CONTACT:
Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.
Condensed Balance Sheet: | ||||||
(In thousands) | December 31, 2022 | December 31, 2021 | ||||
Balance sheet data: | ||||||
Cash and cash equivalents | $ | 161,900 | $ | 341,246 | ||
Short-term investments | 217,271 | 96,850 | ||||
Long-term investments | 4,621 | 64,371 | ||||
Total assets | 558,450 | 626,295 | ||||
Total liabilities | 36,219 | 32,719 | ||||
Total stockholders’ equity | $ | 522,231 | $ | 593,576 |
Consolidated Statement of Operations: | |||||||||||
Three Months Ended December 31, | |||||||||||
(In thousands, except shares and per share data) | 2022 | 2021 | Change | ||||||||
Expenses | |||||||||||
Research and development | $ | 10,741 | $ | 9,010 | $ | 1,731 | |||||
General and administrative | 24,030 | 12,867 | 11,163 | ||||||||
Total operating expenses | 34,771 | 21,877 | 12,894 | ||||||||
Loss from operations | (34,771 | ) | (21,877 | ) | (12,894 | ) | |||||
Other Income (Expense) | |||||||||||
Interest and other income, net | 2,719 | 71 | 2,648 | ||||||||
Net loss | $ | (32,052 | ) | $ | (21,806 | ) | $ | (10,246 | ) | ||
Net loss per common share: Basic and diluted | $ | (1.25 | ) | $ | (0.94 | ) | |||||
Weighted-average common shares outstanding: Basic and diluted | 25,680,520 | 23,096,530 |
Years Ended December 31, | |||||||||||
(In thousands, except shares and per share data) | 2022 | 2021 | Change | ||||||||
Expenses | |||||||||||
Research and development | $ | 42,461 | $ | 27,884 | $ | 14,577 | |||||
General and administrative | 77,735 | 40,391 | 37,344 | ||||||||
Litigation settlement | 25,000 | — | 25,000 | ||||||||
Total operating expenses | 145,196 | 68,275 | 76,921 | ||||||||
Loss from operations | (145,196 | ) | (68,275 | ) | (76,921 | ) | |||||
Other Income (Expense) | |||||||||||
Interest and other income, net | 5,221 | 197 | 5,024 | ||||||||
Interest expense | — | (1,492 | ) | 1,492 | |||||||
Total other income (expense) | 5,221 | (1,295 | ) | 6,516 | |||||||
Net loss | $ | (139,975 | ) | $ | (69,570 | ) | $ | (70,405 | ) | ||
Net loss per common share: Basic and diluted | $ | (5.49 | ) | $ | (3.13 | ) | |||||
Weighted-average common shares outstanding: Basic and diluted | 25,491,721 | 22,196,846 |
Last Trade: | US$184.19 |
Daily Change: | -1.87 -1.01 |
Daily Volume: | 86,190 |
Market Cap: | US$5.290B |
September 06, 2024 August 05, 2024 May 15, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB